Abstract 388P
Background
More and more evidences suggest that circulating tumor cells (CTC) may be a good biomarker, not only as a prognostic indicator for tumors, but also for monitoring therapeutic effect and recurrence. However, the detection of CTC usually requires the final artificial judgment. This requires experienced pathologists and increases their workload. The application of machine learning in medical image recognition can effectively improve the level of automation and reduce the workload. So we hope to use machine learning to identify CTCs.
Methods
First, the python's openCV software package is used to segment the images of CTCs by image denoising, image filtering, edge detection, image expansion and contraction techniques. Secondly, the segmented cell images as a training set are trained using the CNN deep learning network. The CNN deep learning network includes input layer, intermediate hidden layer, and output layer. The middle hidden layer contains three layers, namely layer1, layer2 and lager3. Each intermediate hidden layer further includes convolution layer, excitation layer, and pooling layer. After the input layer, the cell images first enter the first intermediate hidden layer. The convolution layer of the first intermediate hidden layer is composed of 32 5x5 convolution kernels, which are then output to the pooling layer for dimension reduction through the ReLU excitation layer. After dimension reduction, the data is output from the first hidden layer to complete an entire feature extraction process. Then, through the second and third intermediate hidden layers in sequence, all feature extraction is completed. Finally, it enters the output layer and output the result, ie, CTCs or non-CTCs.
Results
We took 2920 cells from 732 patients for training and testing. Among them, 2000 cells were used as training set and 920 cells were used as testing set. The sensitivity and specificity of recognition reached 86.1% and 84.5%, respectively.
Conclusions
To identify CTC by machine learning can reach high sensitivity and specificity. We are further revising our methods of deep learning to achieve greater recognition effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract